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Systematic reviews of diagnostic test 
accuracy (DTA) studies are fundamental 
to the decision making process in 
evidence based medicine. Although 
such studies are regarded as high level 
evidence, these reviews are not always 
reported completely and transparently. 
Suboptimal reporting of DTA systematic 
reviews compromises their validity and 
generalisability, and subsequently their 
value to key stakeholders. An extension 
of the PRISMA (preferred reporting 
items for systematic review and meta-
analysis) statement was recently 
developed to improve the reporting 
quality of DTA systematic reviews. The 
PRISMA-DTA statement has 27 items, of 
which eight are unmodified from the 
original PRISMA statement. This article 
provides an explanation for the 19 new 
and modified items, along with their 
meaning and rationale. Examples of 
complete reporting are used for each 
item to illustrate best practices.
The understanding of diagnostic test performance 
can be enhanced through diagnostic test accuracy 
(DTA) systematic reviews. When performed following 
rigorous methodology, systematic reviews can 
improve our understanding of a specific intervention 
or diagnostic test.1-3 However, published systematic 
reviews, including DTA reviews, are often insufficiently 
informative and therefore of limited use.4-6 Incomplete 
reporting of systematic reviews prevents stakeholders 
who rely on health research from critically assessing 
the quality of evidence and could lead to patient harm, 
misallocation of resources, and research waste.7-9
An extension of the PRISMA (preferred reporting 
items for systematic review and meta-analysis) 
statement was recently developed to facilitate 
complete and transparent reporting of DTA systematic 
reviews, along with another PRISMA extension for 
abstracts.10-12 The PRISMA-DTA statement includes 
27 items; eight of the 27 original PRISMA items were 
unmodified, 17 original items were modified, two new 
items were added, and another two were omitted.
This article is modelled after similar explanation 
and elaboration documents for other reporting 
guidelines.13-17 This document should be used 
concurrently with the PRISMA-DTA statement, which 
includes the PRISMA-DTA checklist (table 1).10 Box 1 also 
explains terminology used throughout the checklist. 
PRISMA-DTA is not meant to be a comprehensive guide 
on how to perform a DTA systematic review; readers are 
directed towards other resources for such guidance, 
such as the Cochrane Handbook for Systematic Reviews 
of Diagnostic Test Accuracy.18
PRISMA-DTA items that were either added or 
modified (relative to the PRISMA statement) are 
discussed in this document, followed by published 
examples of complete reporting for each item. 
Elaboration on the rationale for the inclusion of the 
item, reporting deficiencies, and relevant supporting 
evidence are presented. Items from the original PRISMA 
statement that were not modified for PRISMA-DTA are 
listed but not discussed. An independent explanation 
and elaboration document for the PRISMA-DTA 
checklist for abstracts (in preparation) will expand on 
the rationale for the addition or modification of new 
items and provides examples of optimal reporting of 
abstracts of DTA systematic reviews.
PRISMA-DTA item 1: title
Identify the report as a systematic review (with or 
without meta-analysis) of DTA studies.
Examples
1. Diagnostic accuracy of saline contrast 
sonohysterography in detecting endometrial 
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SUMMARY POINTS 
PRISMA DTA is a checklist of 27 items to guide the reporting of diagnostic 
accuracy systematic reviews
The checklist contains two new items, two omitted items, and 17 modified items 
from the original PRISMA checklist
PRISMA DTA enables transparent and complete reporting that will enhance both 
reproducibility and the ability to determine quality of evidence
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polyps in women with postmenopausal bleeding: 
systematic review and meta-analysis.19
2. Diagnostic accuracy of segmental enhancement 
inversion for diagnosis of renal oncocytoma 
at biphasic contrast enhanced CT [computed 
tomography]: systematic review.20
Explanation
A clear title identifying the work as a systematic 
review and, if conducted, a meta-analysis, of DTA 
studies serves two purposes. It allows readers to 
immediately identify that the study purpose is to 
evaluate diagnostic accuracy, rather than other 
measures of diagnostic performance, and it allows 
for easy identification when searching for or indexing 
systematic reviews.
Authors are encouraged to include relevant terms 
regarding the study participants, index test, target 
condition, and comparisons made, if applicable, 
such that readers can easily locate the study when 
performing a search, and rapidly identify whether 
the systematic review is pertinent to their clinical 
query.
PRISMA-DTA item 2: abstract
The PRISMA-DTA for abstracts checklist (table 2) and 
explanation and elaboration document describe what 
should be reported in the abstract of a DTA review.
PRISMA-DTA item 3 (not modified from original 
PRISMA): rationale
Describe the rationale for the review in the context of 
what is already known.
PRISMA-DTA item D1 (new item): introduction
State the scientific and clinical background, including 
the intended use and clinical role of the index test, and 
if applicable, the rationale for minimally acceptable 
test accuracy (or minimum difference in accuracy for a 
comparative design).
Examples
1. “[S]putum induction is time-consuming, needs 
experienced laboratory personnel, and many 
patients are unable to produce adequate samples. 
Several minimally invasive markers of eosinophilic 
airway inflammation . . . could have potential 
as a surrogate to replace sputum induction, but 
their accuracy to distinguish between patients 
with and without airway eosinophilia remains 
controversial. We did a systematic review and 
meta-analysis to obtain summary estimates of 
the diagnostic accuracy of markers for airway 
eosinophilia in patients with asthma.”21
2. “An a priori minimum diagnostic accuracy for 
DECT [dual energy computed tomography] to 
be considered sufficient was defined as an area 
under the receiver operating characteristic 
(AUROC) curve of 0.95 and a minimum specificity 
of 0.95. These consensus values were based 
on consultation with three fellowship trained 
endourologists who practice in a tertiary care 
center. False positive test results are problematic 
as effective treatment would be delayed due to 
failed dissolution therapy of non-uric acid stones, 
which may cause patient harm. No minimum 
sensitivity has been determined as patients with 
false negative test results would receive current 
standard treatment and are considered at lower 
risk of potential harm than patients with false 
positive test results.”22
Explanation
If the intended use and clinical role of the index 
test being evaluated have not yet been completely 
defined, explicitly stating the exploratory use of the 
index test is recommended, because it will limit just 
how definitive the review can be to support decisions. 
The clinical background in the introduction explains 
the choices that will be made later in the review in 
formulating the review question (item 4), defining 
eligibility criteria (item 6), identifying potential 
applicability concerns (item 12), and interpreting the 
results (item 26).
When evaluating a potential replacement test, a 
systematic review might aim to evaluate whether a 
test confers improved accuracy; in other situations, 
the benefit of a test might be its greater ease of use 
(as in example 1), and the purpose of the review is to 
evaluate whether accuracy is compromised relative to 
more complex alternatives. If possible, the minimally 
acceptable test accuracy of the index test (example 2), 
or difference in test accuracy relative to comparator 
tests that might be used, to detect a condition should 
be provided, with a rationale.
In example 1, the target condition is eosinophilic 
airway inflammation in patients with asthma, because 
patients with eosinophilic airway inflammation are 
more likely to respond to corticosteroid treatment. 
The intended use is treatment selection and the 
potential clinical role is replacement: sputum 
induction is recommended by clinical guidelines (as 
an add-on test to clinical criteria) because applying 
this test in clinical practice has been shown to 
reduce the number of asthma exacerbations but is 
insufficiently feasible. The review aims at identifying 
minimally invasive markers that might replace 
this test in the existing clinical pathway, thereby 
saving time, costs, and effort. The authors do not 
define minimally acceptable test accuracy in this 
example, but a replacement test should generally 
be at least as accurate as the existing test. However, 
other properties might have a role in defining 
the minimally clinically important differences in 
accuracy. For instance, when replacing an invasive 
test with a non-invasive one, some loss of accuracy 
could be tolerated. Similarly, when introducing a 
point-of-care diagnostic test, the benefit of increased 
access and timing might be traded against lower 
accuracy. Whatever the choice made by authors 
regarding minimum accuracy, the rationale for the 
decision should be clearly stated.
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In comparative reviews, the clinical role must be 
specified for each of the index tests. This ensures that 
primary studies are selected with diagnostic pathways 
that specifically address the intended roles of the index 
tests being compared.23
PRISMA-DTA item 4: objectives
Provide an explicit statement of question being 
addressed in terms of participants, index test, and 
target conditions.
Examples
1. “We did a systematic review and meta-analyses 
of studies evaluating the diagnostic accuracy of 
the Elecsys Troponin T high-sensitive assay . . . for 
early diagnosis of acute myocardial infarction in 
patients presenting to the emergency department 
with chest pain”.24
2. “To summarise and compare the accuracy 
of transabdominal ultrasound (TAUS) and 
endoscopic ultrasound (EUS) for the detection of 
Table 1 | PRISMA-DTA checklist
Section/topic Item No PRISMA-DTA checklist item
Title/abstract
Title 1 Identify the report as a systematic review (+/−meta-analysis) of diagnostic test accuracy (DTA) studies
Abstract 2 Abstract: see PRISMA-DTA checklist for abstracts
Introduction
Rationale 3 Describe the rationale for the review in the context of what is already known
Clinical role of index test D1 State the scientific and clinical background, including the intended use and clinical role of the index test, and if applicable, the 
rationale for minimally acceptable test accuracy (or minimum difference in accuracy for comparative design)
Objectives 4 Provide an explicit statement of question(s) being addressed in terms of participants, index test(s), and target condition(s)
Methods
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (eg, web address), and, if available, provide registration 
information including registration number
Eligibility criteria 6 Specify study characteristics (participants, setting, index test(s), reference standard(s), target condition(s), and study design) and 
report characteristics (eg, years considered, language, publication status) used as criteria for eligibility, giving rationale
Information sources 7 Describe all information sources (eg, databases with dates of coverage, contact with study authors to identify additional studies) in 
the search and date last searched
Search 8 Present full search strategies for all electronic databases and other sources searched, including any limits used, such that they could 
be repeated
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if applicable, included in the 
meta-analysis)
Data collection process 10 Describe method of data extraction from reports (eg, piloted forms, independently, in duplicate) and any processes for obtaining 
and confirming data from investigators
Definitions for data extraction 11 Provide definitions used in data extraction and classifications of target condition(s), index test(s), reference standard(s) and other 
characteristics (eg, study design, clinical setting)
Risk of bias and applicability 12 Describe methods used for assessing risk of bias in individual studies and concerns regarding the applicability to the review 
question
Diagnostic accuracy measures 13 State the principal diagnostic accuracy measure(s) reported (eg, sensitivity, specificity) and state the unit of assessment (eg, per 
patient, per lesion)
Synthesis of results 14 Describe methods of handling data, combining results of studies and describing variability between studies. This could include, 
but is not limited to: a) handling of multiple definitions of target condition. b) handling of multiple thresholds of test positivity, c) 
 handling multiple index test readers, d) handling of indeterminate test results, e) grouping and comparing tests, f) handling of 
different reference standards
Meta-analysis D2 Report the statistical methods used for meta-analyses, if performed
Additional analyses 16 Describe methods of additional analyses (eg, sensitivity or subgroup analyses, meta-regression), if done, indicating which were 
prespecified
Results
Study selection 17 Provide numbers of studies screened, assessed for eligibility, included in the review (and included in meta-analysis, if applicable) 
with reasons for exclusions at each stage, ideally with a flow diagram
Study characteristics 18 For each included study provide citations and present key characteristics including: a) participant characteristics (presentation, 
prior testing), b) clinical setting, c) study design, d) target condition definition, e) index test, f ) reference standard, g) sample size, h) 
funding sources
Risk of bias and applicability 19 Present evaluation of risk of bias and concerns regarding applicability for each study
Results of individual studies 20 For each analysis in each study (eg, unique combination of index test, reference standard, and positivity threshold) report 2×2 data 
(TP, FP, FN, TN) with estimates of diagnostic accuracy and confidence intervals, ideally with a forest or receiver operator characteristic 
(ROC) plot
Synthesis of results 21 Describe test accuracy, including variability; if meta-analysis was done, include results and confidence intervals
Additional analysis 23 Give results of additional analyses, if done (eg, sensitivity or subgroup analyses, meta-regression; analysis of index test: failure rates, 
proportion of inconclusive results, adverse events)
Discussion
Summary of evidence 24 Summarise the main findings including the strength of evidence
Limitations 25 Discuss limitations from included studies (eg, risk of bias and concerns regarding applicability) and from the review process (eg, 
incomplete retrieval of identified research)
Conclusions 26 Provide a general interpretation of the results in the context of other evidence. Discuss implications for future research and clinical 
practice (eg, the intended use and clinical role of the index test)
Funding
Funding 27 For the systematic review, describe the sources of funding and other support and the role of the funders
TP=true positives; FP=false positives; FN=false negatives; TN=true negatives. Original version of checklist is also included in the supplementary material.
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Box 1: Terminology
Systematic review
Synthesis of all relevant primary research studies using a rigorous methodological approach to answer a clearly defined research question. With a 
well documented search strategy, identified articles are included in the review if they meet prespecified eligibility criteria. Systematic reviews can 
provide high quality evidence to guide decision making in healthcare, owing to the reliability of the findings derived through systematic approaches 
that minimise bias.
Meta-analysis
Statistical approach for combining results from multiple studies included in a systematic review. Meta-analysis is a common but not a necessary 
component of a systematic review.
Diagnostic test accuracy (DTA) studies
Studies that evaluate the ability of an index test to distinguish between participants with and those without a prespecified target condition. DTA 
studies estimate the sensitivity and specificity of a test. These summary statistics allow for comparisons between the accuracy of different tests.
Index test
Test of interest evaluated in a DTA study. The sensitivity and specificity of the index test are estimated by comparing results of the index test to those 
of a reference standard applied to the same participants.
Reference standard
Test (or combination of tests/procedures) that is deemed to be the best available method to categorise participants as having or not having a target 
condition.
Target condition
Clearly defined health or disease state of participants which the test is used to identify. Evaluation of the performance of an index test depends on 
how accurately it identifies the target condition in study participants.
Risk of bias
Systematic errors that threaten the validity of the findings. In DTA systematic reviews, bias can be due to methodological or clinical misconduct in 
four areas of the included studies, as highlighted in the QUADAS-2 tool: patient selection (eg, were participants enrolled consecutively), index test 
(eg, was the assessment of the index test blinded to the reference standard results), reference standard (eg, is the reference standard sufficiently 
accurate), or flow and timing (eg, is the time between the index test and the reference standard short enough).
Applicability concerns
In a DTA systematic review, concerns regarding applicability can arise when the selection of participants, implementation of the index test, or target 
condition of the primary studies differ from those specified in the review question.
Quality assessment of diagnostic accuracy studies (QUADAS)-2 tool
Tool for the quality assessment of diagnostic accuracy studies that evaluates the quality of individual studies included in a systematic review in terms 
of potential risk of bias, and concerns about applicability to the review question.
Publication bias
Publication bias is when the decision to publish part or all of the results of a study depends on the study findings.
Table 2 | PRISMA-DTA for abstracts checklist
Section/topic Item PRISMA-DTA for abstracts checklist item
Title and purpose
Title 1 Identify the report as a systematic review (+/−meta-analysis) of diagnostic test accuracy (DTA) studies
Objectives 2 Indicate the research question, including components such as participants, index test, and target conditions
Methods
Eligibility criteria 3 Include study characteristics used as criteria for eligibility
Information sources 4 List the key databases searched and the search dates
Risk of bias and applicability 5 Indicate the methods of assessing risk of bias and applicability
Synthesis of results A1 Indicate the methods for the data synthesis
Results
Included studies 6 Indicate the number and type of included studies and the participants and relevant characteristics of the studies (including the 
 reference standard)
Synthesis of results 7 Include the results for the analysis of diagnostic accuracy, preferably indicating the number of studies and participants. Describe test 
accuracy including variability; if meta-analysis was done, include summary results and confidence intervals
Discussion
Strengths and limitations 9 Provide a brief summary of the strengths and limitations of the evidence
Interpretation 10 Provide a general interpretation of the results and the important implications
Other
Funding 11 Indicate the primary source of funding for the review
Registration 12 Provide the registration number and the registry name
Original version of checklist is also included in the supplementary material.
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gallbladder polyps, for differentiating between 
true and pseudo gallbladder polyps . . . in adults”.25
Explanation
The central focus of this item is to describe all 
components of the review questions, with explicit 
reference to participants, index tests, and target 
conditions (PIT), which differs from the traditional 
PICO approach (participants, intervention, control, 
outcome) used in systematic reviews of intervention 
studies. Criteria for considering studies eligible 
for including in a review and search methods for 
identification rely on the PIT criteria.
Tests could have a different accuracy in different 
populations; hence the characteristics of the included 
participants are important. Also, the selection of 
patients, and preceding and subsequent patient care 
steps followed before and after testing might differ 
between settings. Therefore, a description of the 
participants should also include the setting in which 
they were tested. The type of index tests should be 
clearly described, including sufficient detail to ensure 
that readers can understand whether findings are 
generalisable to their practice, and any other details 
specifying the precise nature and application of the 
index tests. The target condition should, if applicable, 
include international standardised terminology 
(eg, the World Health Organization’s International 
Classification of Diseases). All details relating to 
staging, severity, and symptomatology of the condition 
should be included here in order to clearly differentiate 
the target condition being addressed from other, 
possibly similar, conditions.
The comparator should be defined carefully (as often 
done in the PICO approach, for interventional reviews) 
in the review objective because of ambiguity about 
whether this refers to an alternate index test, current 
diagnostic practice, or the reference standard.
PRISMA-DTA item 5 (not modified from original 
PRISMA): protocol and registration
Indicate whether a review protocol exists, indicate 
whether and where it can be accessed (eg, web 
address), and, if available, provide registration 
information including the registration number.
PRISMA-DTA item 6: eligibility criteria
Specify study characteristics (participants, setting, 
index test, reference standards, target conditions, 
and study design) and report characteristics (eg, years 
considered, language, publication status) used as 
criteria for eligibility and providing rationale.
Example
“Patients living in enteric fever-endemic areas attending 
a healthcare facility with fever were eligible . . . All rapid 
diagnostic tests (RDTs) specifically designed to detect 
enteric fever cases [were eligible] . . . Studies may have 
compared one or more RDT against one or more reference 
standards . . . Studies were required to diagnose enteric 
fever using one of the following reference standards: 
(1) bone marrow culture; (2) peripheral blood culture, 
peripheral blood PCR [polymerase chain reaction], 
or both . . . [Target conditions included] typhoid fever 
caused by Salmonella enterica serovar Typhi [and] 
paratyphoid fever caused by Salmonella enterica 
serovar Paratyphi A.”26
Explanation
Eligibility criteria are expected to involve both study 
characteristics and report characteristics, because 
one report might describe more than one study, and 
one study might be described in multiple reports. 
Each of these eligibility criteria should be sufficiently 
described to allow replication, and a rationale 
should be provided when alternatives exist. A clear 
set of inclusion and exclusion criteria successfully 
guides the screening process, and ultimately the 
final selection of what is included in the review, in a 
systematic and reproducible manner. It also informs 
the development of the literature search strategy and 
allows for an appraisal of the validity, applicability, 
and comprehensiveness of the systematic review itself.
For participant and setting characteristics, authors 
are advised to describe any requirements for the 
presentation (eg, specific signs and symptoms such as 
fever), previous diagnostic testing, and, if applicable, 
the clinical settings (eg, healthcare facilities located in 
areas where enteric fever is endemic).
Details on the type of index tests should be provided, 
along with the comparator tests, if applicable. 
Additional details can include a description of who 
is doing the test, and aspects of the testing process 
such as specimen type and handling and transport of 
specimens. For study design, authors should describe 
which type of design is considered, specifically, if both 
comparative and single test accuracy designs will be 
considered, and if any restriction applies for the study 
sample size or the number of diseased participants 
included in a study.
Authors should be explicit on the inclusion of studies 
with multiple groups (also known as multiple gate 
studies, and previously often referred to as diagnostic 
case-control studies).27 These multiple group studies 
can lead to biased estimates of accuracy.28 29 Authors 
should provide a clear definition of the target condition 
and the reference standard(s) that will be considered 
for inclusion. If the topic of interest concerns a 
target condition that can only be established after 
a reasonable length of time, authors are expected 
to specify the length of follow-up required for the 
reference standard.
For reference standards and index tests with 
multiple categories or continuous results, authors 
should specify whether studies are required to report 
outcome data at specific positivity thresholds or result 
categories, or whether data from all thresholds reported 
in primary studies will be included. Comparative DTA 
reviews largely rely on non-comparative primary 
studies, where only one of the index tests has been 
investigated. Inclusion of this study type can lead 
to comparisons made between study populations 
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with different characteristics, varying diagnostic 
pathways, and reference standards.30 31 To reduce this 
source of bias in comparative DTA reviews, authors 
should consider including only comparative primary 
study designs (all patients get all tests, or patients 
randomised to tests)
Eligibility criteria related to study reports typically 
concern language of publication, publication status 
(eg, published, unpublished, in press, or ongoing), 
and year of publication. Complete reporting of 
eligibility criteria for reports ensures reproducibility 
and generalisability.
PRISMA-DTA item 7 (not modified from original 
PRISMA): information sources
Describe all information sources (eg, databases with 
dates of coverage, contact with study authors to 
identify additional studies) in the search and date last 
searched.
PRISMA-DTA item 8: search
Present full search strategies for all electronic 
databases and other sources searched, including any 
limits used so that they can be repeated.
Example
“The search included MEDLINE, Embase, and Cochrane 
Central Register of Controlled Trials (CENTRAL). No 
date restrictions were applied. Language of publication 
was limited to English. Full details of the database 
search including coverage dates for each database are 
presented in appendix 1 [https://link.springer.com/
article/10.1007/s00330-019-06559-0#Sec10].”22
Explanation
Replicability of a systematic review includes 
replicability of the search strategy. The review report 
should provide a complete description of the methods 
used for study retrieval (eg, electronic, grey literature, 
expert contact, reference lists), who did the searches, 
which electronic databases were used, and the dates 
when the searches were performed. This information 
should include the actual search terms for at least one 
of the common bibliographic databases. If the string of 
search terms is too lengthy, it can be reported in the 
appendices of the review (as supplementary material), 
where authors can also indicate how it was modified 
for other databases. Authors should report whether 
the search strategy was reviewed by independent 
information specialists using the evidence based 
guideline for peer review of electronic search 
strategies,32 or using the guidance for describing 
search strings for systematic reviews in the form of 
PRISMA-S (available on the open science framework, 
https://osf.io/ygn9w/).
PRISMA-DTA item 9 (not modified from original 
PRISMA): study selection
State the process for selecting studies (that is, 
screening, eligibility, included in systematic review, 
and, if applicable, included in the meta-analysis).
PRISMA-DTA item 10 (not modified from original 
PRISMA): data collection process
Describe method of data extraction from reports (eg, 
piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from 
investigators.
PRISMA-DTA item 11: definitions for data extraction
Provide definitions used in data extraction and 
classifications of target conditions, index tests, 
reference standards, and other characteristics (eg, 
study design, clinical setting).
Example
“TP [true positive] was considered a diagnosis of 
solid renal mass on DECT [dual energy computed 
tomography] confirmed by the reference standard 
(including RCC [renal cell carcinoma], AML 
[angiomyolipoma], oncocytoma, and renal abscess). 
TN [true negative] was considered a diagnosis of a 
non-solid renal lesion on DECT confirmed by the 
reference standard. FP [false positive] was considered 
a diagnosis of solid renal mass on DECT confirmed to 
be a benign cyst by the reference standard, and FN 
[false negative] was considered a diagnosis of non-
solid lesion on DECT confirmed to be a solid renal mass 
by the reference standard”.33
Explanation
To facilitate the interpretation of the review findings 
and to allow replication, clear definitions should be 
given for extracting data for all critical components of 
the review. This includes the patient population and 
setting, index test and target condition, and reference 
standard, but also the methods used to identify 
patients with the target condition.
Authors are encouraged to report the different 
thresholds for test positivity (whether numerical or 
based on a specific finding) and the different stages and 
grades of disease (or target condition), when applicable 
(eg, tumours). Transparency in the definitions of test 
positivity and target condition is not only fundamental 
for any effort of reproducibility but is also necessary 
for defining disease positivity (in the example, through 
providing the positivity thresholds used based on the 
grade of the tumour).
Authors can refer readers to the study protocol or 
record in a trial registry,34 provide a detailed summary 
of the relevant definitions within their methods section, 
and include extraction forms as a supplementary file.
In many cases when extracting data, review authors 
will need to contact the study investigators with the 
request to provide additional details or to confirm 
extracted data that were not clearly stated in the 
report (eg, method of sampling, the overall number 
of participants with and without the target condition). 
The authors should report in their review which studies 
and variables were identified through this approach. 
The review authors should indicate if any outcome 
data were imputed, for which study and for which 
elements this was done.
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PRISMA-DTA item 12: risk of bias and applicability
Describe methods used for assessing risk of bias 
in individual studies and concerns regarding the 
applicability to the review question.
Example
“Quality assessment of studies was performed using the 
QUADAS [quality assessment of diagnostic accuracy 
studies]-2 tool, examining bias and applicability of the 
studies with respect to four separate domains: patient 
selection, index test, reference standard and the flow 
and timing of patients through the study. No overall 
summary score was calculated, but for each domain, 
any concern with regards to bias and applicability were 
qualified as ‘low’, ‘high’ or ‘unclear’. These results 
were then presented in graph and table form.”35
Explanation
Limitations in the design or conduct of a primary DTA 
study can result in estimates of diagnostic accuracy 
that differ systematically from the truth; this is known 
as “bias” (box 1). Sources of variation are also very 
important to consider when interpreting the results of a 
diagnostic accuracy study. Estimates of accuracy might 
vary because of differences in study populations, how 
the test was conducted or in how the target condition 
is defined. Although estimates of accuracy could be 
unbiased, they might not apply directly to the specific 
review question.36 Potential sources of bias and 
concerns regarding applicability should be considered 
when interpreting the results of a DTA study.
When reporting the results of a DTA systematic 
review, the criteria used to assess the risk of bias 
and concerns regarding the applicability of included 
primary studies should be clearly defined to facilitate 
the interpretation and make replication and update 
possible. This clear definition will allow readers of the 
review to determine whether appropriate criteria were 
used and whether all potential sources of bias and 
applicability were considered.
Authors must also provide details of the selected 
tool and how it was applied. For example, QUADAS 
(quality assessment of diagnostic accuracy studies)-2 
is a systematically developed, evidence based tool 
comprised of four domains: patient selection, index 
test, reference standard, and flow and timing. Each 
domain is assessed in terms of risk of bias, and the first 
three domains are also assessed in terms of concerns 
regarding applicability.37
If QUADAS-2 is used, any modifications to the 
signalling questions should be reported. QUADAS-2 
encourages users to adapt the guidance to make it 
specific to the review, helping reviewers determine 
what would be considered high risk of bias in the 
context of their review question. Any modifications 
to the guidance should also be reported. Space in the 
review text is often insufficient to provide full details 
on rating guidance or modifications, but this can be 
provided as supplementary material.
The process used for assessing risk of bias and 
applicability should also be reported. This information 
includes details such as the number of reviewers 
involved (eg, two independent reviewers), the process 
for resolving disagreements (eg, through discussion 
or referral to a third reviewer), and whether any 
piloting was conducted to achieve consensus on rating 
guidance before assessing all studies.
A description in the methods section of the review 
of how the results of the quality assessment were 
summarised and incorporated into the review is 
recommended. The use of quality scores (scales that 
numerically summarise multiple components into a 
single score) is discouraged; these quality scores have 
been shown to be misleading.38 39 Instead, a description 
of the methods used for an overall assessment of 
risk of bias for one study is preferred. For example, if 
QUADAS-2 is used, guidance suggests that any domain 
judged at high risk of bias makes the whole study at 
high risk of bias.
PRISMA-DTA item 13: diagnostic accuracy measures
State the principal diagnostic accuracy measures 
reported (eg, sensitivity, specificity) and state the unit 
of assessment (eg, per patient v per lesion).
Example
1. “We used the data from the two-by-two tables to 
calculate sensitivity and specificity for each study. 
We present individual study results graphically by 
plotting the estimates of sensitivity and specificity 
(and their 95% confidence intervals) in both forest 
plots and the receiver operating characteristic 
(ROC) space.”40
2. “In our primary meta-analyses, we used the 
individual participant as the unit of analysis 
(that is, any abnormal finding versus none) and 
not individual ultrasound findings. Clinically, it 
is also useful to know the accuracy of individual 
ultrasound findings, as it is plausible that some 
findings are better indicators of tuberculosis than 
others. We therefore determined the accuracy 
of individual ultrasound findings in secondary 
analyses.”41
Explanation
Diagnostic accuracy metrics summarise the 
performance of the test as evaluated against a reference 
standard, which captures the presence of the target 
condition. Many different metrics can be used to express 
a test’s accuracy.42 The most commonly used metrics in 
meta-analyses are sensitivity (the probability of the test 
correctly identifying those with disease) and specificity 
(correctly excluding disease in those without disease).40 
Occasionally meta-analyses summarise positive and 
negative predictive values (probabilities that positive 
and negative test results correctly indicate or exclude 
disease, respectively), diagnostic odds ratios (the ratio 
of the odds of a positive test among individuals with 
the disease relative to those without), or areas under 
receiver operating characteristic (ROC) curves.
The choice of the most appropriate metric should 
be guided by the review question and the preferred 
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study design of the test accuracy studies included in 
the review. For example, the use of a different reference 
standard in test positives and in test negatives can limit 
meaningful calculation of sensitivity and specificity 
when the reference standards have important 
differences in the misclassification rates; instead, 
authors might prefer to calculate and report positive 
and negative predictive values. Diagnostic odds ratios 
are somewhat limited because they do not provide 
information on the numbers of false positives and false 
negatives, for which the consequences typically differ.
The unit of analysis and the type of collected data will 
affect estimates of these metrics. Usually, the presence 
or absence of the target condition is analysed on a per 
patient basis; occasionally a per lesion classification is 
more relevant (eg, where the intervention is delivered 
at lesion level).
PRISMA-DTA item 14: synthesis of results
Describe the methods of handling the data, combining 
the results of the studies, and describing the variability 
between studies. The descriptions could include 
handling of multiple definitions of the target condition, 
handling of multiple thresholds of test positivity, 
handling multiple index test readers, handling of 
indeterminate test results, grouping and comparing 
tests, and handling of different reference standards.
Examples
1. “For each index test, algorithm or checklist 
under consideration, we plotted estimates of 
sensitivity and specificity on coupled forest plots 
and in receiver operating characteristic (ROC) 
space. Where missing or indeterminate results 
were reported, study authors usually did not 
provide sufficient details to allow us to include 
these data in our analyses. Where study authors 
reported missing or indeterminate results in 
more detail, these results were excluded by us for 
consistency.”43
2. “We included studies that defined macrosomia 
[target condition] using either birthweight 
>90th centile or >4000 g in the same meta-
analysis because both are generally considered 
to be similar. However, we also performed 
subgroup analyses considering each definition 
independently.”44
3. “The comparisons made in this review can be 
considered in a hierarchy. The highest level 
comparison groups tests by antibody type (HRP‐2 
versus pLDH) and is formed by combining the 
test types into two groups: HRP‐2 antibody‐based 
(Types 1, 2, 3 and 6) and pLDH antibody‐based 
(Types 4 and 5). However, the data on each test 
type is classified in the primary studies according 
to commercial brands. In order to provide a 
coherent description of the studies contributing 
to each analysis, the results are structured first by 
grouping studies according to their commercial 
brand, then grouping brands to form test types, 
and finally grouping test types by antibody. 
The analytical strategy thus compared the test 
accuracy of commercial brands within each test 
type before making comparisons between test 
types, and then between antibodies. Comparative 
analyses first included all studies with relevant 
data, and were then restricted to studies that 
made direct comparisons between tests with the 
same participants, where such studies existed.”45
Explanation
Choices made regarding handling of data (eg, how 
to combine results of tests with different positivity 
thresholds) in a DTA systematic review may be potential 
sources of bias and variability, as illustrated by the three 
examples. For instance, using the same data to select 
an optimal threshold for positivity and to estimate 
test accuracy, rather than estimating test accuracy at 
a threshold defined a priori, generally overestimates 
test accuracy.30 To obtain clinically meaningful results 
from the narrative or statistical synthesis, factors such 
as multiple thresholds, multiple reference standards, 
multiple target conditions, and multiple index tests 
should be carefully considered during the review 
process, and where relevant, reported with clear 
justification for decisions made (examples 1-2).
For comparative DTA systematic reviews of multiple 
index tests, direct comparisons using head-to-head 
comparisons of multiple index tests are likely to 
have lower risk of bias and higher internal validity. 
However, such comparisons might not be feasible 
owing to the paucity of comparative DTA studies.46 
The alternative strategy of including all eligible studies 
(that is, indirect comparison) should acknowledge the 
potential for differences between test accuracy to be 
confounded by differences in study characteristics. As 
such, reporting whether direct or indirect comparisons 
were used in the review will allow readers to better 
consider the risk of bias when comparing the accuracy 
of multiple index tests (example 3).
Deleted items
Deleted PRISMA-DTA item 15: methods—risk of bias 
across studies
Specify any assessment of risk of bias that might affect 
the cumulative evidence (eg, publication bias, selective 
reporting within studies).
Deleted PRISMA-DTA item 22: results—risk of bias 
across studies
Present results of any assessment of risk of bias across 
studies.
Explanation
Empirical evidence indicates that publication bias 
exists for randomised trials, mainly driven by non-
publication of statistically non-significant results.47 
Publication bias (box 1) or small study effects can 
be identified from funnel plots and tests assessing 
the association between effect estimates and their 
precision.48 Hence, items for reporting investigations of 
the risk of bias across studies are included in PRISMA.
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For DTA studies, although delayed and incomplete 
publication is likely, the determinants and magnitude 
of the bias resulting from the failure to report are 
unclear. Non-comparative DTA studies rarely test 
hypotheses or report P values,49 and no simple 
driver for non-publication exists that is equivalent 
to statistical non-significance. Non-publication of 
findings is likely linked to study results, but definitions 
of low accuracy vary by test and context.
Studies of the link between observed accuracy 
and publication have produced mixed results.50-53 
The Deeks test for detecting publication bias can be 
used while standard tests such as the Egger test are 
not appropriate in the DTA context.54 55 The Deeks 
test has low power to detect publication bias and 
small study effects.54 56 For these reasons, statistical 
investigation of publication and reporting bias is not 
routinely recommended in DTA systematic reviews57 
and these items have been dropped for PRISMA-DTA. 
However, registration and availability of protocols 
for prospective DTA studies is encouraged,34 58 and 
the review should report studies for which results are 
unavailable.
PRISMA-DTA item D2 (new item): meta-analysis
Report the statistical methods used for meta-analyses 
if performed.
Example
“For tests where commonly used thresholds were 
reported we estimated summary operating points 
(summary sensitivities and specificities), with 95% 
confidence and prediction regions using the bivariate 
hierarchical model. Where inadequate data were 
available for the model to converge, we simplified it, 
first by assuming no correlation between estimates 
of sensitivity and specificity and secondly by setting 
estimates of near zero variance terms to zero. Where 
all studies reported 100% sensitivity (or 100% 
specificity), we summed the number with disease (or 
no disease), across studies and used it to compute a 
binomial exact 95% confidence interval.”43
Explanation
Multiple approaches to meta-analysis exist that have 
different limitations and can yield different estimates 
for the same statistic. Therefore, the model used for 
meta-analysis should be reported so that readers can 
consider whether the model selected was suitable.59
DTA systematic reviews will frequently perform 
meta-analysis to aggregate the available evidence into 
a summary measure of sensitivity and specificity, or to 
estimate an underlying summary receiver operating 
characteristic (ROC) curve. Key concepts of meta-
analytical methods include appropriate modelling of 
within study uncertainty in estimates of sensitivity 
and specificity, simultaneous modelling of paired 
sensitivity and specificity statistics allowing for 
the likely negative correlation in estimates across 
studies, and estimation of unexplained variability 
(heterogeneity) in key parameters.60-63
Stating the name of a particular model (eg, the 
bivariate model or the hierarchical summary ROC 
model) with a reference is sufficient, because how such 
models deal with these concepts is well known. But if 
adaptations are made to a standard method (such as 
using a mixed, or a novel model), full descriptions and 
justification are needed.18 59 64
Additional considerations that might apply in some 
reviews include the structure of meta-regression 
models used to investigate sources of variability, 
methods for incorporating multiple thresholds from 
the same study, methods allowing for misclassification 
in the reference standard, and methods for explicit 
comparisons of the accuracy of multiple index tests.18
PRISMA-DTA item 16 (not modified from original 
PRISMA): additional analyses
Describe methods of additional analyses (eg, 
sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were prespecified.
PRISMA-DTA item 17 (not modified from original 
PRISMA): study selection
Provide numbers of studies screened, assessed for 
eligibility, included in the review (and included 
in meta-analysis, if applicable) with reasons for 
exclusions at each stage, ideally with a flow diagram.
PRISMA-DTA item 18: study characteristics
For each included study, provide citations and 
present key characteristics, including participant 
characteristics (presentation, previous testing), clinical 
setting, study design, target condition definition, index 
test, reference standard, sample size, and funding 
sources.
Examples
Supplementary table 1 provides broad detail on the 
nature of the included studies.24 Supplementary table 
2 gives detail on the nature of the tests in each included 
study.65
Explanation
Diagnostic accuracy is not a fixed property of a test. A 
test’s accuracy might vary between settings, patient 
populations, and findings on previous testing. Meta-
analyses of DTA studies often show substantial 
heterogeneity between studies in sensitivity, specificity, 
or both. To assist interpretation and applicability of a 
systematic review’s results, authors should provide 
sufficient details of the key study characteristics that 
might influence test accuracy.
The expected characteristics to be reported relate to 
elements captured in the review’s objective because 
they might depend on previous evidence about 
sources of variability in accuracy and clinical reasons 
for false positive and false negative test results, in 
addition to characteristics considered when assessing 
the risk of bias and concerns about applicability in 
primary studies (see items 12 and 19). Describing the 
characteristics of primary studies is important because 
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it helps readers get a better sense of the variability of 
the studies included in the review.
Supplementary table 1 (and others) are useful 
to present key characteristics of the participants 
(presentation of the target condition, prior testing), 
setting (eg, general practice setting or hospital 
setting, single or multicentre settings), tests (technical 
descriptions of the index test(s), comparator test(s) 
and reference standard(s), including thresholds 
applied), severity of the target condition (eg, locally 
advanced breast cancer or metastatic breast cancer), 
study design, sampling methods (eg, consecutive or 
convenience), avoidance of inappropriate exclusions, 
blinding procedures, and verification procedures 
(eg, complete verification of test results v partial or 
random verification of a sample of test negatives, the 
time interval between execution of the index tests and 
reference standard, and whether all participants were 
included in the analyses).
The fraction of excluded participants and reasons 
for exclusion are of interest, to assess the risk of bias. 
Many of these items are also required reporting for risk-
of-bias assessment (item 19); authors are encouraged 
to consider efficient presentation of these items to 
avoid redundancy in reporting. Languages of published 
papers, years of publication, and geographical origins 
of the included studies can be summarised. The 
funding sources should be stated here, in case of any 
association between sponsorship and estimates of DTA 
that might favour the interests of that sponsor.66
Authors are expected to transparently report the 
source of the included data and how it was accessed. 
For each included study, both published and 
unpublished, authors should provide a full citation 
for the source of their information. Unpublished 
reports could be posted on web repositories (eg, online 
conference abstracts book).
PRISMA-DTA item 19: risk of bias and applicability
Present evaluation of risk of bias and concerns 
regarding applicability for each study (this corresponds 
to item 12 regarding risk of bias and applicability 
methods).
Examples
The following examples illustrate three different 
strategies for presentation of results. Supplementary 
table 3 shows a tabular presentation of results,67 
and supplementary figure 1 provides a graphical 
presentation of results.67 The following text gives a 
narrative summary of results:
“Risk of bias with respect to the index test was rated 
high in one study because it was not reported whether 
the radiologist who interpreted US (index test) was 
blinded to herniography (reference standard), which 
was performed by this same radiologist immediately 
after US. Risk of bias with respect to reference standard 
was rated high in all studies: in all studies, there was 
concern that the reference standard was not blinded 
to US findings, whereas in four studies there was also 
concern that the reference standard could not correctly 
classify the presence or absence of groin hernia. Risk of 
bias with respect to flow and timing was rated high in 
13 studies because not all patients received the same 
reference standard (i.e., presence of verification bias) 
and/or not all patients were included in the analysis. 
Risk of bias with respect to flow and timing was rated 
unclear in two studies because time interval between 
US and reference standard was not reported. There 
were no applicability concerns.”67
Explanation
Reviewers should report the results of their assessment 
of risk of bias and concerns regarding applicability. 
Authors should use graphical displays and figures such 
as those shown in examples 1 and 2 to summarise the 
results of the risk of bias and applicability assessments. 
These results provide an overview of the risk of bias 
and applicability across each domain and within 
individual studies, and should be supplemented by a 
narrative summary of the risk of bias and applicability 
assessment (example 3). As well as providing an 
overall summary of the risk of bias and applicability 
across studies, authors should highlight particular 
domains or signalling questions that were problematic 
in the included studies and highlight studies that 
were at high risk of bias or had concerns regarding 
applicability. Rather than simply specifying which 
domains were at high or unclear risk of bias, reviewers 
are encouraged to provide a more detailed explanation 
as to why they were judged at high or unclear risk of 
bias, and describe the methodological issues specific 
to the review topic that caused concern (example 3).
Results of the risk of bias and applicability 
assessment can be incorporated into the results of 
the review in various ways. These results range from a 
descriptive summary, supported by tables and graphs, 
to statistical incorporation as a means of investigating 
variability, such as stratifying the analysis according 
to risk of bias or applicability concerns, restricting 
inclusion into the review or primary analysis based 
on risk of bias or applicability concerns, or using 
covariates in meta-regression. Each reporting method 
can be done by considering overall study level 
ratings of bias or applicability, or by prespecifying 
individual domains or signalling questions considered 
particularly important to the review topic. Risk-of-bias 
evaluation in comparative accuracy studies remains 
a challenge, because the QUADAS-2 tool does not yet 
include criteria to assess studies comparing multiple 
index tests.37
PRISMA-DTA item 20: results of individual studies
For each analysis in each study (eg, unique 
combination of index test, reference standard, and 
positivity threshold), report 2×2 data (true positives, 
false positives, false negatives, true negatives) with 
estimates of diagnostic accuracy and confidence 
intervals, ideally with a forest plot or a ROC plot. 
Note that the original PRISMA-DTA publication used 
the term “curve” in item 20, but this is incorrect; the 
correct term is “plot.”10
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Examples
A variety of strategies that can be used to report the 
results of individual studies.
1. Supplementary figure 2 shows forest plots for 
detection of sputum eosinophils of 2% or more in 
adults.21
2. Supplementary figure 3 shows an summary ROC 
plot of magnetic resonance imaging, estimated 
fetal weight on two dimensional ultrasound using 
any Hadlock formula at threshold weight higher 
than the 90th centile or more than 4000 g), and 
abdominal circumference more than 35 cm for 
prediction of macrosomia.44
3. Supplementary figure 4 shows summary ROC 
plots of results for the bipolar spectrum diagnostic 
scale, hypomania checklist 32, and mood disorder 
questionnaire, for the detection of bipolar disorder 
in a mental health centre setting.68
4. Supplementary figure 5 shows a summary ROC 
plot of direct comparisons.69
Explanation
Systematic reviews collect the available evidence 
based on previously reported accuracy studies. Access 
to results from individual studies allows readers 
to examine the variability and distribution of test 
accuracy statistics across studies, inspect individual 
study features, verify meta-analysis results, and 
identify potential data extraction errors. Presentation 
of findings from individual studies allows interested 
readers to reproduce the analyses and also apply 
alternative methods (eg, direct pooling of predictive 
values).70 Access to the 2×2 data for each study also 
allows additional analyses to be performed that are not 
specifically considered in the review, such as sensitivity 
analyses and explorations of variability (see item 23).
Essential data to report for each included study 
are complete 2×2 data (true positives, true negatives, 
false positives, and false negatives) and diagnostic 
accuracy statistics of interest with corresponding 95% 
confidence intervals; a table or forest plot might be an 
appropriate method for presentation.
A scatter plot of sensitivity versus specificity 
(summary ROC plot) provides an informative visual 
display that illustrates variability between studies 
in test accuracy. Use of colours and symbols allows 
comparisons between subgroups or test comparisons, 
as shown in supplementary figure 5.69 In systematic 
reviews and meta-analyses that report results for 
multiple thresholds, presenting 2×2 data for all 
primary studies might not be feasible; in such cases, 
authors should consider reporting the complete 2×2 in 
appendices or supplementary materials.
Another useful method of displaying data in 
comparative accuracy systematic reviews is a coupled 
forest plot for sensitivity and specificity57 or coupled 
summary ROC plot as in example 4.71 Appropriate 
grouping and ordering of studies can enhance any 
plot. In supplementary figure 2, for example, studies 
in each subgroup are ordered by the threshold used to 
define test positivity in a forest plot.21
PRISMA-DTA item 21: synthesis of results
Describe test accuracy, including variability; if meta-
analysis was done, include results and confidence 
intervals.
Examples
1. “Substantial heterogeneity was observed as 
shown by the extent of the 95% prediction region 
around the summary point on the summary 
receiver operating characteristic plot .  .  .  The 
summary sensitivity and specificity of 2D 
ultrasound EFW were 0.56 (95% CI [confidence 
interval] 0.49–0.61) and 0.92 (95% CI 0.90–
0.94), respectively.”44
2. “Direct comparisons were based on few head-to-
head studies. The ratios of diagnostic odds ratios 
(DORs) were 0.68 (95% CI 0.12 to 3.70; P = 0.56) 
for urea breath test-13C versus serology (seven 
studies), and 0.88 (95% CI 0.14 to 5.56; P = 0.84) 
for urea breath test-13C versus stool antigen test 
(seven studies). The 95% CIs of these estimates 
overlap with those of the ratios of DORs from the 
indirect comparison.”69
3. “Sensitivities and specificities for differentiating 
FTD from non-FTD ranged from 0.73 to 1.00 
and from 0.80 to 1.00, respectively, for the three 
multiple-headed camera studies. Sensitivities 
were lower for the two single-headed camera 
studies; one reported a sensitivity and specificity 
of 0.40 (95% confidence interval (CI) 0.05 to 0.85) 
and 0.95 (95% CI 0.90 to 0.98), respectively, and 
the other a sensitivity and specificity of 0.36 (95% 
CI 0.24 to 0.50) and 0.92 (95% CI 0.88 to 0.95), 
respectively.”72
Explanation
The generation of summary estimates of the accuracy 
of a diagnostic test (ideally based on all applicable 
studies at low risk of bias) is one of the main 
objectives of DTA systematic reviews. A meta-analysis 
can produce these summary estimates, as means, 
variances, and their covariance. Estimates—especially 
those of the means—should always be accompanied 
by indicators of statistical imprecision, such as 95% 
confidence intervals.
Meta-analysis of DTA studies should ideally rely on 
random effects models, because variability between 
studies is often considerable and cannot be explained 
by chance only. In this case, only presenting summary 
sensitivity and summary specificity with confidence 
intervals can be misleading, because these confidence 
intervals do not reflect the variability between 
studies. Prediction intervals and regions can be used 
as statistics that indicate both the likely location of 
the summary accuracy statistics and the effects of 
variability between studies when enough studies are 
available, and the distributional assumptions are met.
An ROC plot with the individual study estimates 
can include summary ROC curves (supplementary 
figures 4-5)68 69 or summary points with corresponding 
confidence and prediction regions, to visually illustrate 
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statistical uncertainty and variability (example 1). In 
addition, for test comparisons, relative or absolute 
differences can be presented along with confidence 
intervals and P values (example 2). When a meta-
analysis is not possible, the range of results can be 
presented (example 3).
Methods for quantifying or describing heterogeneity 
in DTA systematic reviews used in intervention reviews 
cannot all be applied in DTA reviews. The I2 statistic73 
is not informative for DTA systematic reviews because 
it does not account for potential correlation between 
sensitivity and specificity, for example, owing to 
threshold effects. Multivariate and DTA specific I2 
statistics have been proposed to quantify heterogeneity, 
but they are not well established.71
PRISMA-DTA item 23: additional analyses
Give results of additional analyses, if done (eg, 
sensitivity or subgroup analyses, meta-regression, 
analysis of index test failure rates, proportion of 
inconclusive results, and adverse events).
Examples
1. “A sensitivity analysis including only the five 
studies … that used any Hadlock formula 
incorporating HC [head circumference], AC 
[abdominal circumference] and FL [femur length] 
to compute estimated fetal weight gave similar 
results to the analysis that included studies using 
any version of the Hadlock formula.”44
2. “Subgroup analyses were conducted to investigate 
heterogeneity in sensitivity, and to a lesser degree, 
in specificity . . . Rapid influenza diagnostic tests 
showed a higher pooled sensitivity in children 
(66.6% [CI [confidence interval], 61.6% to 71.7%]) 
than in adults (53.9% [CI, 47.9% to 59.8%]) that 
was statistically significant (P<0.001), whereas 
specificities in the 2 groups were similar. The 
difference in pooled sensitivity between children 
and adults remained statistically significant when 
adjusted for brand of RIDT, specimen type, or 
reference standard.”74
3. “The included studies reported an inconclusive 
result rate of 0.32–5.30%. This issue was further 
compounded by a myriad of varying quality 
control (QC) standards…Some studies investigated 
the reasons for their false and inconclusive results 
and reported these clearly, accounting for all 
samples. Other studies reported inconclusive 
results as false negatives or did not report them 
at all.”75
4. “Serious adverse events from colonoscopy in 
asymptomatic persons included perforations 
(4/10000 procedures, 95% CI, 2-5 in 10000) and 
major bleeds (8/10000 procedures, 95%CI, 5-14 
in 10 000).”76
Explanation
Sensitivity analyses are used to assess whether the 
results of the primary analysis are robust to changes 
in decisions regarding which studies and data are 
included in the meta-analysis, such as the impact of 
using more stringent inclusion criteria for the index 
test44 or excluding studies at high or unclear risk of 
bias.40 Not all sensitivity analyses can be prespecified 
because many issues only become apparent during the 
systematic review process, but authors should clarify 
which analyses were prespecified and which were 
not.1
Investigations of variability are often conducted using 
subgroup analyses and meta-regression. Subgroups 
are typically defined by study level characteristics 
(eg, clinical setting) with summary estimates of test 
accuracy computed for each subgroup.77 Statistical 
comparisons can be made using meta-regression by 
including covariate(s) in models of test accuracy.57 78
In the example, subgroup analysis followed by a 
meta-regression identified differences in sensitivity, 
but not in specificity, between adults and children.74 
Prespecified analyses can be problematic or not 
feasible when the number of studies is small; any 
necessary simplifying assumptions should be 
described.79 Individual participant data allow more 
refined stratification of patients and greater power to 
investigate heterogeneity, but only for characteristics 
that vary at the patient level.77
The presence and nature of inconclusive test results 
might be critical for assessing the usefulness of a test 
in practice. However, such information is often not 
reported or poorly described in primary studies,80 81 
and inconsistency in how such results are handled 
adds to apparent heterogeneity between studies.
Adverse events might occur as a result of the index 
test or reference test,82 and could vary in severity from 
minor discomfort to life threatening complications.76 
The frequency and severity of adverse events might 
influence the clinical usefulness of a test and should 
therefore also be summarised and reported.
PRISMA-DTA item 24: summary
Summarise the main findings including the strength of 
the evidence.
Examples
1. Supplementary table 4 presents a summary of 
findings.83
2. “The principal findings of this systematic review 
were that the diagnostic accuracy of the three main 
groups of commercially available rapid diagnostic 
tests . . . for enteric fever . . . was moderate. There 
was no statistically significant difference in the 
average sensitivity between Typhidot, TUBEX, or 
Test-It Typhoid tests.”26
3. “If the point estimates of the tests for S. 
haematobium are applied to hypothetical 
cohort of 1000 individuals suspected of having 
active S. haematobium infection, among whom 
410 actually have the infection, the strip for 
microhaematuria would be expected to miss 
(102) and falsely identify (77) the least number of 
cases. This test would identify 384 positive cases 
in total.”84
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Explanation
The main findings of the review are typically 
summarised in the first part of the discussion section 
and might also be reported in a summary of findings 
table (example 1). Such structured tables are useful 
for summarising the main study objectives, setting, 
index tests, reference standards, key findings, and 
other information of relevance to readers. Relevant 
information encompasses the summary sensitivity and 
specificity from the primary analysis, which might be a 
comparison between index tests (example 2). The main 
findings should also cover any other objectives of the 
review.
Application of the summary estimates to a 
hypothetical cohort of patients, with a translation 
of the findings using absolute numbers, has been 
shown to help readers in understanding the findings 
(example 3).85 This approach requires specification 
of a prevalence that would be used to re-express 
the sensitivity and specificity estimates in terms of 
predictive values, if required. Care incorporating 
uncertainty about the summary accuracy estimate 
arising from imprecision and heterogeneity would also 
need to be exercised.86
A tool for assessing the quality of the evidence 
and grading the strength of recommendations 
in health care was developed by the Grading of 
Recommendations Assessment, Development and 
Evaluation (GRADE) working group.87-89 However, 
application of the GRADE criteria to DTA systematic 
reviews is challenging, because a clear distinction is 
needed between patient important outcomes and test 
accuracy as the choice outcome.90 Concrete guidance 
regarding translating the QUADAS-2 assessment to the 
corresponding GRADE criteria of indirectness and risk 
of bias could facilitate the use of the GRADE approach 
in DTA systematic reviews; however, this area remains 
a work in progress.90
PRISMA-DTA item 25: limitations
Discuss limitations from included studies (eg, risk 
of bias and concerns regarding applicability) and 
from the review process (eg, incomplete retrieval of 
identified research).
Examples
1. Risk of bias: “There was a high proportion of 
studies at high risk of bias and with high concern 
regarding applicability in all the four domains of 
the QUADAS‐2 tool. This makes the validity and 
applicability of the results questionable.”69
2. Applicability: “Furthermore, almost all in-person 
evaluations of dermoscopy used in conjunction 
with visual inspection had high concerns for the 
applicability of the included population and half 
had high concern for the applicability of the test. 
The restriction of including only excised lesions 
and the small number of studies conducted in a 
limited prior testing population mean that our 
results cannot be extrapolated to a primary care 
population.”43
3. Review: “We were unable to perform all the 
investigations of heterogeneity that we had 
originally intended to because the data simply 
were not available.”91
Explanation
The limitations section should include the validity of 
the findings (that is, risk of bias based on QUADAS-2), 
generalisability of the findings (that is, applicability 
based on QUADAS-2), and any limitations of the review 
process itself (eg, low number of included studies).
Incomplete reporting in primary studies could 
hamper interpretation of findings, and biases within 
the included publications (such as the reporting of 
accuracy results for only high-performing thresholds of 
continuous or ordinal tests) can distort meta-analytical 
results. Incomplete retrieval of relevant publications 
might also contribute to bias, if the omitted studies 
differ substantively from those included in the meta-
analysis.
All threats to the validity and generalisability of 
the review should be discussed, with suggestions on 
how these factors could have influenced the reported 
synthesised results, including magnitude and direction 
of possible biases. Reviewers are encouraged to provide 
a more detailed explanation as to why certain domains 
were judged at high or unclear risk of bias, and to 
describe the methodological issues specific to the review 
topic that caused concern, rather than simply specifying 
which domains were at high or unclear risk of bias.
PRISMA-DTA item 26: conclusions
Provide a general interpretation of the results in the 
context of other evidence. Discuss implications for 
future research and clinical practice (eg, the intended 
use and clinical role of the index test).
Examples
1. “The most important conclusion from this 
review is that CEA [carcinoembryonic antigen] 
has inadequate sensitivity to be used as the sole 
method of detecting recurrence. Most national 
guidelines already recommend that it should 
be used in conjunction with another mode of 
diagnosis (such as CT [computed tomography] 
imaging of the thorax, abdomen, and pelvis at 12 
to 18 months) to pick up the remaining cases. Our 
review supports this recommendation. If CEA is 
used as the sole triage test, a significant number 
of cases will be missed, whatever threshold is 
adopted for defining a positive test.”92
2. “Future studies that evaluate the diagnostic 
accuracy of non-sputum-based tests for 
tuberculosis, such as LF-LAM [lateral flow 
urine lipoarabinomannan assay], in people 
living with HIV should use a reference standard 
that includes at least two different specimens 
(eg sputum, and urine), and in addition, 
for presumed extrapulmonary tuberculosis, 
appropriate specimens from the suspected sites of 
involvement.”93
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Explanation
The conclusions of a test accuracy systematic review 
should consider the results of the analyses, taking 
into account the intended use and clinical role of the 
index test in clinical practice, as well as limitations 
of the review, such as risk of bias and applicability 
concerns.94
In the discussion, authors should consider whether 
the index test is sufficiently accurate for the proposed 
role in the clinical pathway.23 Conclusions will ideally 
reflect persistent uncertainty: Were the summary 
estimates after meta-analysis sufficiently precise? Were 
the included studies of sufficient quality? Could the 
results be applied to the clinical setting in which the 
test is likely to be used?95
Recent evidence suggests that systematic reviews of 
diagnostic accuracy studies often spin their results: 
authors, for example, arrive at strong recommendations 
regarding the use of a test in clinical practice despite 
having identified relatively low accuracy for the test 
under evaluation.94 Such overinterpretation can be 
avoided by carefully taking into account the required 
accuracy for the destined role of the test in the clinical 
pathway.
Even if adequate accuracy of a test is demonstrated, 
the effectiveness (clinical utility) and cost effectiveness 
of the test when used in practice needs to be verified, 
and complementary non-accuracy evidence could 
already exist to answer these additional questions. 
Authors should note this condition particularly if they 
are making a strong recommendation for change to 
clinical practice.
PRISMA-DTA item 27 (not modified from original 
PRISMA): funding
For the systematic review, describe the sources of 
funding and other support and the role of the funders.
Additional considerations
The PRISMA-DTA reporting guideline is a minimum 
set of items to inform readers about the review process 
and its findings, and to enable quality appraisal and 
assessment of generalisability of the review findings.10
Although all DTA systematic reviews share basic 
methodological approaches, different subspecialties 
might have individual considerations to report. 
Therefore, authors are encouraged to include any 
additional information deemed necessary to allow 
readers to critically evaluate the findings and replicate 
the research. For example, interobserver variability is 
understood to be an important facet of imaging DTA 
research.96 As such, reporting of statistics relevant to 
assessing this variability (eg, ĸ coefficients) could be 
relevant to imaging research.
DTA meta-analyses of ordinal index tests could have 
bias if included primary studies only report results 
from well performing thresholds, and if the thresholds 
reported differ across primary studies. This problem 
has been raised as a concern in mental health tests, 
and authors should report how they handle missing 
threshold data.97
With the growing evidence supporting the 
correlation between adherence to reporting guidelines 
and study quality, orchestrated strategies should 
be dedicated towards implementing PRISMA-DTA 
into research practices.98 These approaches could be 
achieved on the journal level, by encouraging adoption 
of PRISMA-DTA and giving journal peer reviewers the 
option of using the PRISMA-DTA checklist as part of a 
manuscript peer review process, or on the author level, 
through organising workshops and raising awareness 
of PRISMA-DTA. Computerised analysis of manuscripts 
for compliance with PRISMA-DTA, as has been done 
for CONSORT (consolidated standards of reporting 
trials), would greatly decrease barriers to evaluating 
completeness of reporting.
With the increasing number of DTA systematic 
reviews, several emerging advances might be relevant 
to DTA systematic reviews. The implementation of 
machine learning in the identification of relevant 
DTA articles for inclusion in systematic reviews could 
increase efficiency, automate relatively daunting tasks, 
and yield a broader recall of identified articles.99 
However, the underlying algorithms of such processes 
are not yet fully understood. Whatever methods of 
article identification are used, readers will benefit 
from a complete description of the process. With the 
challenges arising from the poor reporting of artificial 
intelligence driven primary research in DTA,100 the 
development of reporting guidelines specifying 
the minimum parameters to be reported for these 
algorithms could improve our understanding and allow 
for the use of their results in meta-research. Similar 
guidelines are available for individual participant 
data.3 101
Conclusion
This explanatory document aims to provide a resource 
for authors seeking guidance in what to include in 
a report of a DTA systematic review. We encourage 
authors to use this article when seeking a more 
comprehensive explanation of each item included 
in the PRISMA-DTA statement. We hope that these 
resources, along with the associated website (http://
www.prisma-statement.org/Extensions/DTA), help 
improve the complete and transparent reporting of 
DTA systematic reviews.
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